


# INA RESPOND

INDONESIA RESEARCH PARTNERSHIP ON INFECTIOUS DISEASES



2021  
ACCOMPLISHMENTS

*THREE international multi-center studies on COVID-19: 1) An International SARS-CoV-2 Infection Observational Study (ICOS Study); 2) An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial for the Safety, Tolerability of Adult Hospitalized Patients at Onset of Clinical Progression of COVID-19 (ITAC Study); and 3) International study on COVID-19 Vaccine to assess Immunogenicity, Reactogenicity and Efficacy (InVITE Study).*

**GOAL 1: Generate knowledge, disseminate results, and promote utilization of research findings**

## PUBLICATIONS

- ❖ **Review of Current COVID-19 Diagnostics and Opportunities for Further Development**, *Frontiers in Medicine*, May 2021.
- ❖ **Approach to identifying causative pathogens of Community-Acquired Pneumonia in children using culture, molecular, and serology tests**, *Frontier in Pediatrics*, May 2021.
- ❖ **Maintaining international research collaborations in the setting of a pandemic: Approach in Indonesia**, *Journal of Global Health*, July 2021.
- ❖ **Prevalence of HIV infection and Resistance Mutations in Patients Hospitalized for Febrile Illness in Indonesia**, *American Journal of Tropical Medicine & Hygiene*, August 2021.
- ❖ **Sharia (Islamic Law) Perspective of COVID-19 Vaccine**, *Frontiers in Tropical Diseases*, December 2021.

## COVID-19 WEBINAR SERIES

1. **One Year Living with SARS-COV-2: Progress on Prevention and Treatment**, 10 April 2021.
2. **COVID-19 Diagnosis Update, Pathogenesis and Co-Infections**, 24 July 2021.
3. **COVID-19 Progress on Prevention and Treatment**, 4 December 2021.

## STUDIES

- **ITAC INSIGHT 013** - Clinical Trial Study  
Total randomized: **33**. Study Completed  
3 hospitals study sites
- **ICOS INSIGHT 011** - Observational Study  
Total enrolled: **357**. Study Completed  
2 hospitals study sites
- **ORCHID** - Observational Study, ongoing  
Interim total enrolled: **153**  
2 hospitals study sites
- **InVITE** - Observational Study, ongoing  
Interim total enrolled: **497**  
3 hospitals study sites
- **D2EFT** - Clinical Trial Study, ongoing  
Interim total randomized: **46**  
4 hospitals study sites
- **PROACTIVE** - Observational Study, ongoing  
Total enrolled: **4,336**  
19 hospitals study sites
- **TRIPOD** - Observational Study  
Total enrolled: **490**. Study Completed  
7 hospitals study sites

## GOAL 2: Build INA-RESPOND as a sustainable research network capable of conducting excellent clinical

### COLLABORATIONS

- SubDit HIV/AIDS
- SubDit Tuberculosis (TB)
- SubDit Vector and Zoonosis
- NIAID/NIH
- INSIGHT
- NCI/NIH
- US-CDC
- USAID/PEER Health
- RePORT
- The Kirby Institute/UNSW
- CUIMC/Columbia University
- WHO
- PT Prodia Diacro Laboratories
- PT Ganesha Aggies Jaya
- CREID/EID-SEARCH
- Eijkman/EOCRU

### TRAININGS

- GCP Training
- Data Management Training
- Laboratory Training
- Clinical Research Protocol Writing Training
- Scientific Writing Support for Sites
- Studies-specific Training and Refresher Training for Sites
- NIAID HIV Lecture Series
- Clinical Research Project Management Training
- INA-RESPOND SOPs Training
- Studies SOPs Training
- NIH Information & Security Privacy Awareness Refresh Training
- Orientation and Training for new hires

### STUDIES SITES

- Site 510 - Hasan Sadikin Hospital
- Site 520 - Sanglah Hospital
- Site 521 - Udayana University Hospital
- Site 530 - Cipto Mangunkusumo Hospital
- Site 540 - Suliarti Saroso Hospital
- Site 550 - Wahidin Sudirohusodo Hospital
- Site 560 - Kariadi Hospital
- Site 570 - Soetomo Hospital
- Site 580 - Sardjito Hospital
- Site 590 - Persahabatan Hospital
- Site 600 - Adam Malik Hospital
- Site 610 - Tangerang Hospital
- Site 630 - Ansari Saleh Hospital
- Site 640 - Saint Carolus Hospital
- Site 650 - Budi Kemuliaan Batam Hospital
- Site 660 - Wahab Sjahranie Hospital
- Site 670 - Zainoel Abidin Hospital
- Site 680 - Soedarso Hospital
- Site 690 - Abepura Hospital
- Site 700 - TC Hillers Hospital

## GOAL 3: Achieve organizational excellence

### OPERATIONS

INA-RESPOND established and enhanced network capabilities in the following areas:

- Ten Core Sites and Ten Study Specific Sites
- Reference Laboratory
- Data Management Center
- Policies and SOPs
- IT Operations Infrastructure and Network
- Website
- Monthly Newsletter
- Scientific Manuscript Writing Guidebook



### VISION

*Become the premier research network in the region providing evidence to inform policy making, minimize the impact of infectious diseases and improve human well-being.*

### MISSION

*Improve the health of the people of Indonesia and benefit the international community, by conducting high-quality infectious disease research through a collaborative, sustainable, and well-recognized research network.*

### VALUES

- Beneficial and Responsive to the research needs of Indonesia and the international community
- Innovative in designing, implementing, and integrating research in a healthcare setting
- Goal-Oriented to achieve the mission of the network
- High-Quality in conducting scientifically sound and ethical infectious disease research
- Trust and Teamwork with respect, transparency, communication, collaboration, and shared responsibility

[www.ina-respond.net](http://www.ina-respond.net)